Vaxcyte, Inc. (PCVX)

Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $8.80 billion. The enterprise value is $7.26 billion.

Market Cap	8.80B
Enterprise Value	7.26B

Important Dates

The next estimated earnings date is Wednesday, May 6, 2026, after market close.

Earnings Date	May 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 143.92 million shares outstanding. The number of shares has increased by 11.55% in one year.

Current Share Class	143.92M
Shares Outstanding	143.92M
Shares Change (YoY)	+11.55%
Shares Change (QoQ)	+0.17%
Owned by Insiders (%)	0.67%
Owned by Institutions (%)	95.81%
Float	132.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.95
P/TBV Ratio	3.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.91, with a Debt / Equity ratio of 0.04.

Current Ratio	7.91
Quick Ratio	7.81
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -25.59% and return on invested capital (ROIC) is -18.68%.

Return on Equity (ROE)	-25.59%
Return on Assets (ROA)	-17.72%
Return on Invested Capital (ROIC)	-18.68%
Return on Capital Employed (ROCE)	-33.02%
Weighted Average Cost of Capital (WACC)	11.72%
Revenue Per Employee	n/a
Profits Per Employee	-$1.51M
Employee Count	507
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +88.67% in the last 52 weeks. The beta is 1.39, so Vaxcyte's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	+88.67%
50-Day Moving Average	57.59
200-Day Moving Average	44.66
Relative Strength Index (RSI)	56.41
Average Volume (20 Days)	1,375,478

Short Selling Information

The latest short interest is 13.69 million, so 9.51% of the outstanding shares have been sold short.

Short Interest	13.69M
Short Previous Month	13.07M
Short % of Shares Out	9.51%
Short % of Float	10.35%
Short Ratio (days to cover)	10.59

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-923.68M
Pretax Income	-766.63M
Net Income	-766.63M
EBITDA	-907.28M
EBIT	-923.68M
Earnings Per Share (EPS)	-$5.63

Balance Sheet

The company has $1.56 billion in cash and $117.48 million in debt, with a net cash position of $1.44 billion or $10.03 per share.

Cash & Cash Equivalents	1.56B
Total Debt	117.48M
Net Cash	1.44B
Net Cash Per Share	$10.03
Equity (Book Value)	2.69B
Book Value Per Share	20.49
Working Capital	1.42B

Cash Flow

In the last 12 months, operating cash flow was -$655.58 million and capital expenditures -$56.97 million, giving a free cash flow of -$712.55 million.

Operating Cash Flow	-655.58M
Capital Expenditures	-56.97M
Depreciation & Amortization	16.40M
Net Borrowing	n/a
Free Cash Flow	-712.55M
FCF Per Share	-$4.95

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.55%
Shareholder Yield	-11.55%
Earnings Yield	-8.81%
FCF Yield	-8.19%

Analyst Forecast

The average price target for Vaxcyte is $88.25, which is 44.31% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$88.25
Price Target Difference	44.31%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1